Cyanotech Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2324373016
USD
0.36
0.01 (2.86%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Cyanotech Corp. stock-summary
stock-summary
Cyanotech Corp.
Pharmaceuticals & Biotechnology
Cyanotech Corporation is engaged in the production of natural products derived from microalgae for the nutritional supplements market. The Company's products include Hawaiian Spirulina Pacifica and Hawaiian BioAstin. Hawaiian Spirulina Pacifica is a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids. Hawaiian BioAstin is a dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health. The Company cultivates over two microalgal species from which its product lines, natural astaxanthin products and spirulina products, are derived. The Company produces its algae in Hawaii and manufactures the finished products in Hawaii and California.
Company Coordinates stock-summary
Company Details
73-4460 Queen Kaahumanu Hwy Ste 102 , KAILUA KONA HI : 96740-2637
stock-summary
Tel: 1 808 32613531 310 3466131
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.12%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Michael Davis
Independent Chairman of the Board
Dr. Gerald Cysewski
Chief Executive Officer, Executive Vice Chairman of the Board
Ms. Nancy Katz
Independent Director
Mr. Walter Menzel
Independent Director
Mr. David Mulder
Independent Director
Mr. David Vied
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.04

stock-summary
Return on Equity

-36.59%

stock-summary
Price to Book

0.26